Q2 Earnings Estimate for TARS Issued By HC Wainwright

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - HC Wainwright issued their Q2 2025 earnings per share estimates for Tarsus Pharmaceuticals in a research note issued on Tuesday, May 27th. HC Wainwright analyst M. Caufield expects that the company will post earnings of ($0.41) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $72.00 target price on the stock. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals' Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($2.10) EPS, FY2027 earnings at $0.76 EPS, FY2028 earnings at $0.44 EPS and FY2029 earnings at $0.89 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.05. The business had revenue of $78.34 million during the quarter, compared to analysts' expectations of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%.

Several other research analysts have also weighed in on the company. Guggenheim lifted their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a research note on Monday. They issued an "outperform" rating and a $75.00 price target on the stock. Barclays dropped their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Tarsus Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $66.67.

Tarsus Pharmaceuticals Price Performance

Shares of TARS traded up $0.37 during mid-day trading on Thursday, reaching $43.32. The company had a trading volume of 223,007 shares, compared to its average volume of 700,443. The company's 50-day moving average is $46.93 and its 200-day moving average is $48.96. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The company has a market capitalization of $1.82 billion, a P/E ratio of -11.41 and a beta of 0.94. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, General Counsel Bryan Wahl sold 3,341 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the transaction, the general counsel now owns 58,057 shares of the company's stock, valued at approximately $2,687,458.53. This represents a 5.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bobak R. Azamian sold 8,534 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $427,638.74. Following the completion of the transaction, the chief executive officer now directly owns 53,635 shares in the company, valued at $2,687,649.85. The trade was a 13.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,542 shares of company stock worth $1,581,173 over the last 90 days. Company insiders own 8.25% of the company's stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in TARS. Rhumbline Advisers boosted its holdings in shares of Tarsus Pharmaceuticals by 4.3% in the 1st quarter. Rhumbline Advisers now owns 51,682 shares of the company's stock valued at $2,655,000 after purchasing an additional 2,148 shares in the last quarter. Strs Ohio bought a new position in Tarsus Pharmaceuticals during the 1st quarter worth $288,000. Jane Street Group LLC raised its position in shares of Tarsus Pharmaceuticals by 105.8% in the 1st quarter. Jane Street Group LLC now owns 10,456 shares of the company's stock worth $537,000 after acquiring an additional 190,000 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Tarsus Pharmaceuticals by 2.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company's stock worth $3,659,000 after purchasing an additional 1,394 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Tarsus Pharmaceuticals by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company's stock worth $1,137,000 after purchasing an additional 1,217 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.